GSK reports promising early results in ovarian and womb cancer drug trial
Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drug...
Redirecting to full article...
Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drug...
Redirecting to full article...